News & Investors

Want to stay updated? Subscribe to our newsletters. For free.

Have questions? Our live support would be happy to help you.

PDF 266 KB

Berlin (Germany) and Germantown, MD (U.S.A.), November 2, 2015 –

Epigenomics AG (Frankfurt Prime Standard: ECX, OTCQX: EPGNY), the German-American cancer molecular diagnostics company, announced today that it will host a corporate workshop at the Association for Molecular Pathology (AMP) 2015 Annual Meeting. Attendees of AMP, analysts, investors and media representatives are cordially invited to join this event on November 4, 2015, at 4pm CDT in room 17A at the Austin Convention Center, Austin, TX.

The workshop will provide an update on Epigenomics’ colorectal and lung cancer programs. First, the Company will present trials demonstrating patient willingness to accept Septin9 plasma screening for colorectal cancer. Subsequently, an update on the deployment of the Septin9 test into the clinical laboratory setting will be provided. Finally, data on the performance of the company’s liquid biopsy marker panel using Real-Time PCR methylation detection for lung cancer detection will be presented. Following the workshop, there will be an opportunity for discussion of the studies and applications for epigenetic biomarkers in oncology with Epigenomics’ technology group.

The workshop will be hosted by Dr. Thomas Taapken, CEO/CFO of Epigenomics AG, and Noel Doheny, CEO of Epigenomics’ US subsidiary. Presentations will be held by:

  • Theo deVos PhD, Director, Development & Commercial Operations, North America Epigenomics, Inc.,
    “Will the Availability of a Blood Test Increase CRC Screening Participation in the Non-Adherent Population?”
  • Nicholas Potter, PhD, FACMG, Executive Vice President, Clinical Affairs, Molecular Pathology Laboratory Network, Inc. Maryville, TN
    “Cancer Screening: Bringing Blood-based Epigenetic Cancer Testing into the Clinical Laboratory”
  • Uwe Staub PhD, Chief Operating Officer, Epigenomics AG, Berlin, Germany
    “An Emerging Tool for Lung Cancer Management”

“We are highly committed to drive innovation in the field of blood-based cancer detection using our epigenetic tests,” said Dr. Thomas Taapken, CEO/CFO of Epigenomics AG. “In this respect, AMP 2015 represents an important opportunity to share new data from our colorectal and lung cancer programs with the medical and laboratory community.”

About Epigenomics

Epigenomics is a molecular diagnostics company focused on blood-based detection of cancers using its proprietary DNA methylation biomarker technology. The Company develops and commercializes diagnostic products across multiple cancer indications with high medical need. Epigenomics’ lead product, Epi proColon(R), is a blood-based screening test for the early detection of colorectal cancer and is currently marketed in Europe and China. For more information, visit www.epigenomics.com.

Contact Epigenomics AG

Peter Vogt

Investor & Public Relations

Epigenomics AG

Tel +49 (0) 30 24345 368

ir@epigenomics.com

www.epigenomics.com

For U.S. press inquiries:

Epigenomics, Inc.

20271 Goldenrod Lane, Suite 2027

Germantown, Maryland 20876

pr@epigenomics.com

Epigenomics legal disclaimer

This communication expressly or implicitly contains certain forward-looking statements concerning Epigenomics AG and its business. Such statements involve certain known and unknown risks, uncertainties and other factors which could cause the actual results, financial condition, performance or achievements of Epigenomics AG to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Epigenomics AG is providing this communication as of this date and does not undertake to update any forward-looking statements contained herein as a result of new information, future events or otherwise.

The information contained in this communication does not constitute nor imply an offer to sell or transfer any product, and no product based on this technology is currently available for sale by Epigenomics in the United States or Canada. The analytical and clinical performance characteristics of any Epigenomics product based on this technology which may be sold at some future time in the U.S. have not been established.